Related Experiment Video

Updated: May 11, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP

Min Lu1, Hilde Breyssens, Victoria Salter

  • 1Ludwig Institute for Cancer Research, University of Oxford, Oxford OX3 7DQ, UK.

Cancer Cell
|April 30, 2013
PubMed

Insights

Nearly 90% of melanomas inactivate wild-type p53. Researchers found cyclin B1/CDK1-phosphorylated iASPP promotes nuclear entry and p53 inhibition, offering a new therapeutic target for melanoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Wild-type p53 is inactivated in approximately 90% of human melanomas, with mechanisms largely unknown.
  • Understanding p53 inactivation is crucial for developing effective melanoma treatments.

Purpose of the Study:

  • To elucidate the mechanisms of wild-type p53 inactivation in melanoma.
  • To identify novel therapeutic targets for melanoma treatment.

Main Methods:

  • Investigated the role of iASPP phosphorylation by cyclin B1/CDK1 in regulating p53.
  • Analyzed nuclear iASPP levels in melanoma metastasis and patient samples.
  • Utilized small molecules to inhibit MDM2 and iASPP phosphorylation.
  • Evaluated the combined effect of p53 reactivation and BRAFV600E inhibition in vivo.

Main Results:

  • Cyclin B1/CDK1-mediated phosphorylation inhibits iASPP dimerization, promoting nuclear entry of iASPP monomers and enhancing p53 inhibition.
  • Nuclear iASPP is associated with melanoma metastasis and reduced patient survival.
  • Melanoma cell lines with wild-type p53 express high levels of phosphorylated nuclear iASPP, MDM2, and cyclin B1.
  • Inhibition of MDM2 and iASPP phosphorylation induced p53-dependent apoptosis and growth suppression.
  • Concurrent p53 reactivation and BRAFV600E inhibition demonstrated additive suppression in vivo.

Conclusions:

  • Phosphorylated iASPP plays a key role in wild-type p53 inactivation in melanoma.
  • Targeting iASPP phosphorylation and MDM2 presents a potential therapeutic strategy for melanoma.
  • Combined inhibition of p53 and BRAFV600E offers a promising therapeutic approach for melanoma.

More Related Videos

Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...